Sign In
Buy CLRB
$2.57
+0.0400 (+1.58%)
At Close: Jul 31, 2026
Cellectar Biosciences Expands Global Intellectual Property Estate
08:05am, Tuesday, 17'th Feb 2026
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing A
Following Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom's Macroglobulinemia (WM), Expects to Su
Perrigo (NYSE:PRGO) & Cellectar Biosciences (NASDAQ:CLRB) Critical Survey
01:16am, Tuesday, 23'rd Dec 2025
Cellectar Biosciences (NASDAQ: CLRB - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
03:41pm, Thursday, 13'th Nov 2025
Cellectar Biosciences, Inc. ( CLRB ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:20am, Thursday, 13'th Nov 2025
Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scienti
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models CLR 225 (225Ac-phospholipid ether) Demo
Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
08:05am, Thursday, 11'th Sep 2025
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Sol
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
08:05am, Tuesday, 09'th Sep 2025
Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Tr
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
08:45am, Friday, 05'th Sep 2025
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
12:25pm, Thursday, 14'th Aug 2025
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Chad J. Kolean - VP, CFO & Secretary James V.
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
07:19am, Thursday, 14'th Aug 2025
Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Onc
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
08:05am, Thursday, 07'th Aug 2025
FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ
